Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Blinatumomab + Methotrexate + Nivolumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Blinatumomab||Blincyto||anti-CD19/anti-CD3 recombinant bispecific|monoclonal antibody MT103|MEDI-538||CD19 Antibody 14||Blincyto (blinatumomab) is a bispecific antibody that binds both CD19 on B-cells and the CD3 complex on T-cells, therefore facilitates T-cell mediated killing of CD19-expressing tumor cells (PMID: 26337639). Blincyto (blinatumomab) is FDA approved for the treatment of B-cell precursor acute lymphoblastic leukemia in adult and children negative for BCR-ABL1 (FDA.gov).|
|Methotrexate||Abitrexate||Amethopterin||Chemotherapy - Antimetabolite 14||Methotrexate is an antimetabolite, which inhibits DHFR resulting in decreased immune function and antineoplastic activity and is FDA approved for psoriasis, RA, and several cancers including choriocarcinoma, AML, lung, head and neck and epidermoid (FDA.gov).|
|Nivolumab||Opdivo||MDX-1106|BMS-936558||Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 89||Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) in patients with melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, in combination with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent NSCLC without EGFR or ALK alterations, in combination with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, in combination with Cabometyx (cabozantinib) in patients with advanced renal cell carcinoma, and in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04546399||Phase II||Blinatumomab + Methotrexate + Nivolumab Dexamethasone + Pegaspargase + Vincristine Sulfate Blinatumomab + Methotrexate Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Leucovorin + Mercaptopurine + Methotrexate + Thioguanine + Vincristine Sulfate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Leucovorin + Methotrexate + Nivolumab Blinatumomab + Dexamethasone + Methotrexate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Methotrexate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Methotrexate + Nivolumab Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Dexamethasone + Methotrexate + Nivolumab Dexamethasone + Mercaptopurine + Methotrexate + Vincristine Sulfate||A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)||Recruiting||USA | CAN||2|